El interés en corto de Eli Lilly da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Eli Lilly. Los datos de interés en corto se actualizan cada dos semanas.

Eli Lilly (NYSE:LLY) Bolsa, Informe de interés en corto

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

Biotech

Large Cap

News

Health Care

Movers

General

Novo Nordisk revela datos sobre Amycretina, un nuevo medicamento para pérdida de peso, que mostró una baja del 13,1% en peso en 12 semanas.

Novo Nordisk presenta resultados de su nuevo fármaco para pérdida de peso, Amycretina

Earnings

Pre-Market Outlook

Markets

Trading Ideas

BLBD

USFD

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este jueves: LLY, BLBD, USFD, OM y PH.

5 acciones en el foco este jueves: LLY, BLBD, USFD, OM y PH

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

<a href="https://storage.courtlistener.com/recap/gov.uscourts.txnd.395430/gov.uscourts.txnd.395430.30.0.pdf" title="https://storage.courtlistener.com/recap/gov.uscourts.txnd.395430/gov.uscourts.txnd.395430.30.0.pdf">https://storage.courtlistener.com/recap/gov.uscourts.txnd.395430/gov.uscourts.txnd.395430.30.0.pdf</a> &nbsp;

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Shares Of Hims & Hers Health See Volume; Traders Circulate Court Filing Regarding Shortage Of Lilly's Tirzepatide Shortage, Parties Agree To Maintain Stay As Ordered By Court In October 2024, With Joint Status Report Due By December 19, 2024, Or Within Seven Days Of FDA's New Decision

Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has seen better days. The stock is up 26.04% for the last year but has struggled recently, falling 17.57% over <a href="https://www.benzinga.com/quote/LLY/news">the last month</a>.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM.png" alt="" class="wp-image-658564" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Lilly stock is well below its summer highs and is trading at $746.94 at the time of writing. The once red-hot obesity drugmaker is in the crosshairs of bearish technicals and political uncertainty.
Could the selloff be an overreaction?
Read Also: <a href="https://www.benzinga.com/24/11/42097813/eli-lilly-opts-to-develop-candidate-for-nervous-system-disease">Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate</a>
<h2 class="wp-block-heading">Bearish Signals Galore For LLY Stock</h2>
Lilly stock is trading beneath its eight-, 20-, and 50-day exponential moving averages, firmly positioning it in a bearish trend. The Relative Strength Index (RSI) of 33.02 indicates the stock is teetering on oversold territory, while the MACD at negative 37.55 confirms strong downward momentum.
Even the 200-day simple moving average of $835.76 is now a distant memory, amplifying concerns.
<h2 class="wp-block-heading">Kennedy Sends Drugmakers Tumbling</h2>
The broader selloff in anti-obesity drugmakers like Eli Lilly, Novo Nordisk AS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) has been linked to fears over the possible appointment by President-elect Donald Trump of Robert F. Kennedy Jr. as head of the Department of Health and Human Services.
Investors worry his critical stance on GLP-1 weight-loss treatments could lead to reduced insurance coverage or pricing pressures. While the agency has limited power to enact sweeping changes without Congress, the uncertainty has spooked the market.
<h2 class="wp-block-heading">Still Room To Run?</h2>
For contrarian investors, the fundamentals paint a different picture. Eli Lilly's Zepbound and Mounjaro sales are projected to hit $18 billion by 2026, doubling from 2024 estimates.
Total revenue is expected to climb to $69 billion by 2026, with earnings soaring to $30 per share — more than double the current $13.26.
And at 33.2 times forward earnings (per <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">Benzinga Pro</a> data), the stock's valuation looks far more attractive than its July peak of 57.2 times.
<h2 class="wp-block-heading">What's Next?</h2>
Jim Cramer's take sums up the contrarian sentiment: "This stock is as hated now as it was loved not that long ago. I think it's a buy&#8230; enough on the selling."
For long-term investors, Eli Lilly's dominance in the burgeoning obesity drug market remains a compelling growth story. 
Whether the selloff is a red flag or a golden opportunity may depend on how much faith investors have in the fundamentals.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42097386/cvs-healthcignaunitedhealths-pharmacy-benefit-managers-accuse-ftc-of-overreach-in-effort-to-reshape-drug-rebate-system">Big Pharma&#8217;s Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System</a></li>
</ul>
Photo courtesy of Eli Lilly.

Long Ideas

Technicals

Politics

AMGN

Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs

A notable insider purchase on November 20, was reported by Ralph Alvarez, Board Member at Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), based on the most recent SEC filing.
What Happened: In a significant move reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947824000260//Archives/edgar/data/59478/000005947824000260/0000059478-24-000260-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, Alvarez purchased 318 shares of Eli Lilly, demonstrating confidence in the company's growth potential. The total value of the transaction stands at $231,749.
The latest update on Thursday morning shows Eli Lilly shares down by 1.52%, trading at $741.94.
<h3>Unveiling the Story Behind Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Breaking Down Eli Lilly's Financial Performance</h3>
Revenue Growth: Over the 3 months period, Eli Lilly showcased positive performance, achieving a revenue growth rate of 20.43% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 81.02%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Eli Lilly's EPS is below the industry average. The company faced challenges with a current EPS of 1.08. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 2.19, Eli Lilly faces challenges in effectively managing its debt levels, indicating potential financial strain.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 81.19 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 16.67 is above industry norms, reflecting an elevated valuation for Eli Lilly's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Eli Lilly's EV/EBITDA ratio of 59.36 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Exploring Key Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000059478">Check Out The Full List Of Eli Lilly's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Ralph Alvarez Boosts Confidence With $231K Purchase Of Eli Lilly Stock

A notable insider purchase on November 20, was reported by J. Erik Fyrwald pursuant to authorization on file, Director at Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), based on the most recent SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947824000264//Archives/edgar/data/59478/000005947824000264/0000059478-24-000264-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday unveiled that file made a notable purchase of 320 shares of Eli Lilly, valuing at $233,089.
Eli Lilly shares are trading down 1.56% at $741.66 at the time of this writing on Thursday morning.
<h3>All You Need to Know About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Eli Lilly's Economic Impact: An Analysis</h3>
Revenue Growth: Eli Lilly displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 20.43%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 81.02%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Eli Lilly's EPS is below the industry average. The company faced challenges with a current EPS of 1.08. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.19, caution is advised due to increased financial risk.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: Eli Lilly's current Price to Earnings (P/E) ratio of 81.19 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 16.67 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 59.36 is above the industry average, suggesting that the market values the company more highly for each unit of EBITDA. This could be attributed to factors such as strong growth prospects or superior operational efficiency.
</li>
</ul>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insider transactions serve as a piece of the puzzle in investment decisions, rather than the entire picture.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000059478">Check Out The Full List Of Eli Lilly's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Eli Lilly Director Trades $233K In Company Stock

Mary Lynne Hedley, Board Member at Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), reported an insider buy on November 20, according to a new SEC filing. 
What Happened: Hedley's recent purchase of 315 shares of Eli Lilly, disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947824000266//Archives/edgar/data/59478/000005947824000266/0000059478-24-000266-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, reflects confidence in the company's potential. The total transaction value is $229,916.
The latest update on Thursday morning shows Eli Lilly shares down by 1.56%, trading at $741.66.
<h3>Discovering Eli Lilly: A Closer Look</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Breaking Down Eli Lilly's Financial Performance</h3>
Revenue Growth: Eli Lilly's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 20.43%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: Achieving a high gross margin of 81.02%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Eli Lilly's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 1.08.
</li>
</ul>
Debt Management: Eli Lilly's debt-to-equity ratio surpasses industry norms, standing at 2.19. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 81.19, Eli Lilly's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 16.67 is above industry norms, reflecting an elevated valuation for Eli Lilly's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 59.36 is above the industry average, suggesting that the market values the company more highly for each unit of EBITDA. This could be attributed to factors such as strong growth prospects or superior operational efficiency.
</li>
</ul>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Understanding Crucial Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000059478">Check Out The Full List Of Eli Lilly's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Massive Insider Trade At Eli Lilly

Disclosed in the latest SEC filing, a significant insider purchase on November 20, involves Kimberly H Johnson, Board Member at Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
What Happened: Johnson's recent purchase of 315 shares of Eli Lilly, disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947824000270//Archives/edgar/data/59478/000005947824000270/0000059478-24-000270-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, reflects confidence in the company's potential. The total transaction value is $229,666.
As of Thursday morning, Eli Lilly shares are down by 1.56%, currently priced at $741.66.
<h3>Unveiling the Story Behind Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Eli Lilly's Economic Impact: An Analysis</h3>
Revenue Growth: Eli Lilly displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 20.43%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 81.02%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Eli Lilly's EPS is below the industry average. The company faced challenges with a current EPS of 1.08. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Eli Lilly's debt-to-equity ratio surpasses industry norms, standing at 2.19. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Eli Lilly's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 81.19.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 16.67 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Eli Lilly's EV/EBITDA ratio of 59.36 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Important Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000059478">Check Out The Full List Of Eli Lilly's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Eli Lilly Board Member Trades $229K In Company Stock

In a recent SEC filing, it was revealed that Juan R Luciano, Board Member at Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), made a noteworthy insider purchase on November 20,.
What Happened: Luciano demonstrated confidence in Eli Lilly by purchasing 322 shares, as reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947824000274//Archives/edgar/data/59478/000005947824000274/0000059478-24-000274-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total value of the transaction is $234,833.
Tracking the Thursday's morning session, Eli Lilly shares are trading at $741.66, showing a down of 1.56%.
<h3>Discovering Eli Lilly: A Closer Look</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Financial Milestones: Eli Lilly's Journey</h3>
Revenue Growth: Over the 3 months period, Eli Lilly showcased positive performance, achieving a revenue growth rate of 20.43% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 81.02%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Eli Lilly's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 1.08.
</li>
</ul>
Debt Management: Eli Lilly's debt-to-equity ratio stands notably higher than the industry average, reaching 2.19. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 81.19 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 16.67, Eli Lilly's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 59.36 reflects market recognition of Eli Lilly's value, positioning it as more highly valued compared to industry peers.
</li>
</ul>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Navigating the World of Insider Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000059478">Check Out The Full List Of Eli Lilly's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Confidence On Display: Juan R Luciano Acquires $234K In Eli Lilly Stock

On November 20, Gabrielle Sulzberger, Director at Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) executed a significant insider buy, as disclosed in the latest SEC filing.
What Happened: In a significant move reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947824000276//Archives/edgar/data/59478/000005947824000276/0000059478-24-000276-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, Sulzberger purchased 315 shares of Eli Lilly, demonstrating confidence in the company's growth potential. The total value of the transaction stands at $229,916.
Eli Lilly shares are trading down 1.56% at $741.66 at the time of this writing on Thursday morning.
<h3>Discovering Eli Lilly: A Closer Look</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Eli Lilly: Delving into Financials</h3>
Revenue Growth: Eli Lilly's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 20.43%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 81.02%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Eli Lilly's EPS is below the industry average. The company faced challenges with a current EPS of 1.08. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 2.19, Eli Lilly faces challenges in effectively managing its debt levels, indicating potential financial strain.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: Eli Lilly's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 81.19.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 16.67 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio of 59.36, the company's market valuation exceeds industry averages.
</li>
</ul>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Cracking Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000059478">Check Out The Full List Of Eli Lilly's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Eye On Growth: Gabrielle Sulzberger Adds $229K Of Eli Lilly Stock To Portfolio

On Wednesday, Verge Genomics announced that Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)&nbsp;has opted to pursue the development of therapeutics against two validated drug targets for amyotrophic lateral sclerosis (ALS) as part of the companies&#8217; collaboration, which was <a target="_blank" href="https://www.benzinga.com/general/biotech/21/07/21892739/eli-lilly-verge-genomics-ink-720m-pact-for-amyotrophic-lateral-sclerosis-therapies" rel="noreferrer noopener">initiated in July 2021</a>.
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig&#8217;s disease, is a nervous system disease that affects the nerve cells in the brain and spinal cord.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42070751/eli-lillys-investigational-drug-cuts-sticky-cholesterol-levels-by-almost-86" rel="noreferrer noopener">Eli Lilly&#8217;s Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%</a>
Verge&#8217;s AI-enabled CONVERGE&nbsp;platform identified and validated the targets, with 83% of prioritized targets validated in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42082756/verge-genomics-announces-milestones-in-collaboration-with-lilly-to-discover-and-develop-novel-trea" rel="noreferrer noopener">disease-relevant models</a>.
Target selection triggered near-term milestone payments from Lilly to Verge. As the programs progress, Verge is eligible for additional downstream economics.
In 2021, Verge and Lilly entered a three-year collaboration to discover and validate novel therapeutic targets for ALS that would become the focus for subsequent drug discovery and development.
Verge received up to $25 million in upfront equity investment and potential near-term milestones, with a total deal value of $694 million plus potential downstream royalties.
Verge also continues to advance VRG50635, its internal lead drug candidate for sporadic and familial ALS.
VRG50635 is currently being evaluated in a Phase 1B Proof-of-Concept (PoC) study in Canada and several European countries. Enrollment is complete and dose escalation, including to the highest dose level, is ongoing.
Price Action: Eli Lilly stock is up 2.75% at about $749 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42093116/global-e-surges-as-gmv-and-revenue-outperform-expectations-in-q3" target="_blank" rel="noreferrer noopener">Global-E Soars: Q3 Sales Surge 32%, FY24 Outlook Raised Amid GMV Boom</a></li>
</ul>

Contracts

Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate

The Federal Trade Commission (FTC) is facing legal challenges from three competing pharmacy-benefit managers (PBMs) over its attempt to restrict their ability to negotiate drug prices for <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41256923/cvs-unitedhealth-request-ftc-chair-recusal-amid-ongoing-pharmacy-benefit-managers-lawsuit" rel="noreferrer noopener">health plan sponsors</a>.
In September, the FTC filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark,&nbsp;Cigna Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), Express Scripts, and&nbsp;UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Optum—for allegedly engaging in unfair and anti-competitive practices that have inflated the list&nbsp;<a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">price of insulin medications</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The&nbsp;complaint&nbsp;accuses the PBMs of creating a system that benefits them financially by prioritizing drug rebates, forcing patients to pay higher costs for life-saving insulin. These PBMs, referred to as the Big Three, administer around 80% of <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">prescriptions in the U.S</a>.
The PBMs argue that this action seeks to upend current drug rebate contracts and disrupt long-standing practices, all while expanding the FTC&#8217;s authority beyond traditional limits.
The companies also <a target="_blank" href="https://www.bloomberglaw.com/public/desktop/document/ExpressScriptsIncetalvFederalTradeCommissionetalDocketNo424cv0154?doc_id=X11H3MUIQJ4995RQ9NSUPGSE2AP" rel="noreferrer noopener">contend</a> that the administrative proceeding violates constitutional principles by lacking independent judicial oversight and claim that the FTC&#8217;s approach could result in significant and irreparable injury.
The lawsuit stems from the FTC&#8217;s attempt to regulate the drug rebate system, allowing PBMs to secure manufacturers&#8217; discounts.
However, the FTC&#8217;s complaint accuses the PBMs of using their power to create an unfair market, alleging that the system allows drug manufacturers to inflate prices.
In challenging the FTC&#8217;s action, the PBMs argue that this is not just a market dispute but a constitutional issue.
They assert that the FTC&#8217;s administrative proceeding, taking place in an in-house forum where the agency decides the facts, the law, and the outcome, is unconstitutional.
Furthermore, the PBMs argue that the FTC&#8217;s decision to handle the case through this in-house process, with a partisan panel of Democratic commissioners, deprives them of a fair trial.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42094248/trumps-return-boosts-palantir-national-security-bets-drive-140-billion-market-cap" target="_blank" rel="noreferrer noopener">Palantir Tech&#8217;s $140 Billion Market Cap Gain Is Driven By Trump&#8217;s Victory And Higher Defense Spending Hope &#8211; Is The Stock Overvalued?</a></li>
</ul>
Photo by towfiqu barbhuiya via unsplash

Government

Regulations

Legal

Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System

WIIM

Eli Lilly shares are trading higher after Verge Genomics announced a collaboration with the company to discover and develop novel treatments for ALS.

— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics' AI-Enabled, All-in-Human CONVERGE Platform
— Demonstration of the Robust Predictive Power of CONVERGE&#xAE; - 83% of Prioritized Targets were Validated in Disease-Relevant Models, a Rate Significantly Higher than Industry Standards

Verge Genomics Announced Milestones In Collaboration With Lilly To Discover And Develop Novel Treatments For ALS; Lilly To Develop Two Targets Identified By Verge Genomics

In 2025, Walker will collaborate with Lilly on certain digital commercial activities.
Moeller is the chairman of the board, president and chief executive officer of Procter &amp; Gamble (P&amp;G).&nbsp;

Management

Eli Lilly Elects Jon Moeller As New Member Of Its Board, Effective Dec. 1, 2024; Karen Walker To Transition Her Role, Resigning As Member Of Board, Effective Dec. 31, 2024

Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) shares have nosedived 12.5% month-to-date through Nov. 19, putting the stock on track for its worst monthly performance since February 2009, when <a href="https://www.benzinga.com/quote/LLY/news">it tumbled 20.2%. </a>
The pharmaceutical giant, which ranks 11th by market capitalization in the S&amp;P 500 and holds the top spot among health care stocks, is reeling from a disappointing third-quarter earnings report and lowered guidance.
The sell-off raised doubts about the near-term prospects for Lilly's high-profile drugs Mounjaro and Zepbound, which missed revenue expectations and contributed to a storm of investor uncertainty.
For traders, the burning question now is whether Eli Lilly's pullback represents an opportunity to "buy the dip" in a high-quality, highly profitable company that maintains a position of dominance in the health care market.
<h1 class="wp-block-heading">Chart: LLY Shares On Track For Worst Month In Over 15 Years</h1>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197-1024x501.png" alt="" class="wp-image-655565" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197-1024x501.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197-768x376.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197-1536x752.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19124450/image-197.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h1 class="wp-block-heading">The Catalyst: Weak Third-Quarter Earnings and Downgraded Guidance</h1>
Eli Lilly's third-quarter earnings report, released on Oct. 30, triggered the stock's steep decline in November.
While the company has been riding high on the success of its diabetes and obesity drugs, Mounjaro and Zepbound, both underperformed this quarter, missing revenue expectations by 14% and 26%, respectively.
Alec W. Stranahan, an analyst at Bank of America, said, "The focus this quarter was again on Mounjaro and Zepbound, which missed revenue expectations by a wide margin."
In response to the weak performance, Eli Lilly adjusted its full-year revenue guidance. 
The company lowered the high end of its forecast, projecting $45.4 billion to $46 billion, down from the previous range of $45.4 billion to $46.6 billion.
Lilly management attributed the third-quarter shortfall to temporary "inventory dynamics" rather than a fundamental decline in demand, reassuring investors that this was not indicative of a broader problem with its flagship drugs.
The company also highlighted its ongoing direct-to-consumer (DTC) promotional efforts, which began in the third quarter and are expected to drive sales growth in the fourth quarter and into 2025.
Despite the negative quarter, Bank of America remains bullish on Eli Lilly despite the recent stumble. Stranahan reaffirmed his "Buy" rating on the stock with a 12-month price target of $1,100, implying a 55% upside from current levels.
Instead, Goldman Sachs took a more cautious stance, maintaining a "Neutral" rating on Eli Lilly with a 12-month price target of $890, implying a 24% upside from current levels.
Chris Shibutani, M.D., described the third quarter as a "challenging update" and flagged the $1 billion shortfall in tirzepatide revenues as a significant concern. 
He expressed skepticism about whether the company can achieve its revised fourth quarter and 2025 revenue guidance.
The analyst urges caution ahead, highlighting that Eli Lilly's guidance assumes significant execution on multiple fronts, from inventory management to international expansion. "These factors need to cooperate for LLY to deliver," Shibutani said.
<h1 class="wp-block-heading">How Did Eli Lilly Shares React After Double-Digit Monthly Sell-offs?</h1>
Double-digit monthly selloffs have been a rarity for Eli Lilly, with only four occurrences in the past 15 years where the stock dropped more than 10% in a single month.
Interestingly, past data shows Eli Lilly has historically rebounded strongly following such declines.
Here's how the stock performed one month and three months after these major sell-offs:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Month</th>
<th>LLY Monthly Loss (%)</th>
<th>LLY 1-Month Forward (%)</th>
<th>LLY 3-Month Forward (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>October 2020</td>
<td>-11.9%</td>
<td>+11.6%</td>
<td>+59.5%</td>
</tr>
<tr>
<td>September 2021</td>
<td>-10.6%</td>
<td>+10.2%</td>
<td>+19.8%</td>
</tr>
<tr>
<td>January 2022</td>
<td>-11.2%</td>
<td>+14.6%</td>
<td>+28.4%</td>
</tr>
<tr>
<td>July 2024</td>
<td>-11.2%</td>
<td>+24.1%</td>
<td>+2.3%</td>
</tr>
</tbody>
</table>
</figure>
While history doesn't guarantee future results, the data suggests that Eli Lilly shares have demonstrated resilience following steep sell-offs, with gains ranging from 10.2% to 24.1% one month later and a solid average of positive returns over three months.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/42041147/novo-nordisk-to-offer-wegovy-in-china-at-fraction-of-usa-cost">Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip?

On Monday,&nbsp;Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)&nbsp;announced Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a) [Lp(a)], a genetically inherited risk <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42047055/lillys-muvalaplin-lowered-lipoprotein-a-levels-in-adults-with-high-risk-for-cardiovascular-events-" rel="noreferrer noopener">factor for heart disease</a>.
In the U.S., about 20% of people, or approximately 63 million individuals, have high levels of Lp(a).
Elevated Lp(a) levels can double or even triple the risk of a heart attack and are associated with other cardiovascular issues.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/42039286/eli-lillys-zepbound-mounjaro-shows-cardiovascular-benefits-in-patients-with-obesity-related-heart-failure" rel="noreferrer noopener">Eli Lilly&#8217;s Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure</a>
The study demonstrated that muvalaplin significantly reduced elevated Lp(a) levels in adults, meeting its primary endpoint.
At the 12-week primary endpoint, muvalaplin (10 mg, 60 mg, and 240 mg) significantly reduced Lp(a) levels compared to placebo.
The placebo-adjusted reductions were up to 85.8% using an intact Lp(a) assay and up to 70.0% using an apo(a) assay.
<ul>
<li>Specifically, the reductions were 47.6% (10 mg), 81.7% (60 mg) and 85.8% (240 mg) with the intact Lp(a) assay, and 40.4% (10 mg), 70.0% (60 mg) and 68.9% (240 mg) with the apo(a) assay.</li>
</ul>
Muvalaplin also met secondary endpoints for all three tested doses (10 mg, 60 mg, and 240 mg).
<ul>
<li>The three tested doses achieved statistical significance for Lp(a) thresholds, and the 60 mg and 240 mg doses also achieved statistical significance for apoB reductions.</li>
</ul>
These data also demonstrated:
<ul>
<li>Using the intact Lp(a) assay, the percentage of participants achieving normal Lp(a) levels of less than 125 nmol/L at week 12 was 64.2% (10 mg), 95.9% (60 mg), and 96.7% (240 mg), compared to 6.0% in the placebo group.</li>
<li>Using the apo(a) assay, 38.9% (10 mg), 81.9% (60 mg), and 77.4% (240 mg) of participants achieved an Lp (a) level of less than 125 nmol/L, compared to 3.6% in the placebo group.</li>
<li>ApoB levels were reduced at all doses, with placebo-adjusted reductions of 8.9% (10 mg), 13.1% (60 mg) and 16.1% (240 mg).</li>
</ul>
Adverse events were similar in both the muvalaplin and placebo groups.
Price Action: LLY stock is down 0.44% at $723.97&nbsp;at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42060801/walmart-tops-q3-estimates-ecommerce-growth-shines-with-27-lifts-full-year-forecast" target="_blank" rel="noreferrer noopener">Walmart Q3 Earnings: Revenue Beat, eCommerce Growth Shines, Issues Bullish Outlook For FY25</a></li>
</ul>
Photo by Jonathan Weiss via Shutterstock

Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%

Eli Lilly Canada Inc. (Lilly Canada) is disappointed and strongly disagrees with Canada's Drug Agency (CDA-AMC)'s Final Recommendation for Ebglyss&#x2122;&nbsp;(lebrikizumab), published on Friday, November 15, 2024. The CDA-AMC recommended&nbsp;that Ebglyss not be reimbursed by public drug plans, excluding Quebec, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults and adolescents 12 years of age and older.1
Lilly Canada stands behind Ebglyss as a first-line biological therapy for the treatment of atopic dermatitis and we remain committed to patients. Access to Ebglyss for new and existing patients with moderate-to-severe AD via LillyPlus&#xAE;&nbsp;will not change as we tenaciously pursue options for private and public reimbursement in Canada. We have shared our concerns with the CDA-AMC leadership and believe that the CDA-AMC are applying differential standards to biologic therapies for the treatment of AD that are not founded upon their own requirements. Lilly Canada continues to explore all options to overcome this recommendation.

Global

Eli Lilly Canada Is Disappointed And Strongly Disagrees With Canada's Drug Agency's Final Recommendation For Ebglyss, Published On Friday, November 15, 2024; CDA-AMC Recommended That Ebglyss Not Be Reimbursed By Public Drug Plans, Excluding Quebec, For Moderate-To-Severe Atopic Dermatitis

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is a buy. &#8220;This stock is as hated now as it was loved not that <a href="https://www.benzinga.com/markets/equities/24/11/42039286/eli-lillys-zepbound-mounjaro-shows-cardiovascular-benefits-in-patients-with-obesity-related-heart-failure">long ago,&#8221; he added</a>.
Eli Lilly on Monday said Muvalaplin met secondary endpoints for <a href="https://www.benzinga.com/pressreleases/24/11/n42047055/lillys-muvalaplin-lowered-lipoprotein-a-levels-in-adults-with-high-risk-for-cardiovascular-events-">all three tested doses.</a>
Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) is a &#8220;winner,&#8221; Cramer said.
On Monday, Needham analyst John Todaro maintained Coinbase with a Buy and raised the price target from $290 to $375.
Cramer said IES Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NASDAQ">IESC</a>) is a &#8220;terrific&#8221; infrastructure play.
IES Holdings will release fiscal 2024 fourth quarter and year-end results before the opening bell on Friday, Nov. 22.
&#8220;I do think that Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is just a traditional kind of semiconductor company,&#8221; Cramer said. He added that he prefers Texas Instruments Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) to that one.
Semtech will release the financial results of its third quarter of fiscal year 2025 after the closing bell on Monday, Nov. 25.
&#8220;It is an incredibly expensive stock versus the rest of the market,&#8221; Cramer said when asked about Cameco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>). &#8220;I am a ‘ka-ching ka-ching' when it comes to Cameco.&#8221;
On Nov. 7, Cameco raised its FY24 revenue guidance.
The &#8220;Mad Money&#8221; host said he likes Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>).
Marvell Technology will release its third-quarter fiscal year 2025 financial results on Tuesday, Dec. 3, followed by a conference call to discuss the results.
Cramer said own Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and not trade it. &#8220;I would wait for a dip because the bears are all over it every minute of the day. Keep that in mind, and then pull the trigger,&#8221; he added.
A consumer group called &#8220;Which?&#8221; recently filed a £3 billion ($3.81 billion) legal claim against Apple, accusing the tech giant of breaching UK competition law <a href="https://www.benzinga.com/news/global/24/11/41964915/apple-faces-legal-action-over-rip-off-icloud-charges-could-pay-out-38b-to-uk-customers">through its iCloud service</a>.
Price Action:
<ul>
<li>Eli Lilly shares fell 2.6% to settle at $727.20 on Monday.</li>
<li>Apple shares gained 1.3% to close at $228.02.</li>
<li>Coinbase shares gained 6.4% to close at $325.41.</li>
<li>IES shares climbed 2.6% to settle at $264.67 during the session.</li>
<li>Semtech shares gained 3.9% to close at $45.84 on Monday.</li>
<li>Cameco shares gained 4.3% to settle at $55.90 during the session.</li>
<li>Marvell shares gained 1% to close at $88.71 on Monday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></li>
</ul>
Photo: Shutterstock

Media

AAPL

COIN

IESC

MRVL

SMTC

Jim Cramer: Coinbase Is A 'Winner,' Suggests Buying This 'Hated' Big Pharma Stock

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 41 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 46% leaning bullish and 26% bearish. Among these notable options, 27 are puts, totaling $1,787,322, and 14 are calls, amounting to $807,770.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $520.0 to $950.0 for Eli Lilly over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Eli Lilly options trades today is 358.06 with a total volume of 1,100.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly's big money trades within a strike price range of $520.0 to $950.0 over the last 30 days.
<h3>Eli Lilly Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732031174_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$57.7</td>
<td>$52.75</td>
<td>$55.5</td>
<td>$650.00</td>
<td>$416.2K</td>
<td align="right">153</td>
<td align="right">77</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$44.15</td>
<td>$41.2</td>
<td>$43.0</td>
<td>$850.00</td>
<td>$129.0K</td>
<td align="right">0</td>
<td align="right">20</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$59.5</td>
<td>$57.1</td>
<td>$57.1</td>
<td>$720.00</td>
<td>$119.9K</td>
<td align="right">211</td>
<td align="right">23</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$233.5</td>
<td>$226.4</td>
<td>$229.83</td>
<td>$950.00</td>
<td>$114.9K</td>
<td align="right">66</td>
<td align="right">0</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$71.85</td>
<td>$70.2</td>
<td>$70.2</td>
<td>$750.00</td>
<td>$112.3K</td>
<td align="right">200</td>
<td align="right">19</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Eli Lilly's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,880,416, the price of LLY is down by -0.65%, reaching $722.49.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 77 days from now.</li>
</ul>
<h3>What The Experts Say On Eli Lilly</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $1068.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Eli Lilly, targeting a price of $975. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1100. 
&#x2A; An analyst from Wolfe Research has revised its rating downward to Outperform, adjusting the price target to $1000. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1250. 
&#x2A; An analyst from Deutsche Bank has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1015. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Eli Lilly Unusual Options Activity

Eli Lilly Says Muvalaplin Met Secondary Endpoints For All Three Tested Doses

Lilly's Muvalaplin Reduces Lipoprotein(a) Levels By Up To 85% In High-Risk Cardiovascular Patients In Phase 2 Study; Results Published In JAMA And Presented At AHA 2024 Scientific Sessions

Citi notes that the FDA said in a status report filed in a Texas court that it needs more time to determine if Eli Lilly's (LLY) tirzepatide should...

FDA tirzepatide status report 'moderately positive' for Hims & Hers, says Citi

Eli Lilly Stock: Unexpected Developments (Rating Downgrade)

Novo Nordisk said to have contracted Ypsomed to make next gen obesity drug's pens

BTIG raised the firm's price target on Protagonist Therapeutics (PTGX) to $67 from $51 and keeps a Buy rating on the shares. The company's PN-881 i...

Protagonist Therapeutics price target raised to $67 from $51 at BTIG

Sanofi (SNY) is planning changes to its 340B plan on how it gives discounts to certain hospitals, planning to require institutions to provide pharm...

Sanofi planning changes to 340B hospital drug discount plan, WSJ reports

Sanofi becomes latest drugmaker to challenge HHS over 340B drug-discount program

Nvidia's Big Buildup, Then A Shrug

Sanofi is reportedly planning to introduce changes to how it offers discounted drugs to hospitals with low-income and uninsured patients

Sanofi (SNY) Is Seeking to Change How It Gives Discounts to Hospitals

AbbVie: Upgrading To 'Strong Buy' After Pullback

Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC

ABBV

ALHC

AMZN

AZNCF

BIIB

CLOV

COST

GILD

GLAXF

MRNA

NONOF

NVDA

PTGX

REGN

SNYNF

SPGI

TEVA

TEVJF

WDAY

YPHDF

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-24 at 12.03.42 AM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Press Releases

Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products

Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium

Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting

Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics' Founders to Company's Scientific Advisory Board

Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks

Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity

Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose

Lilly announces changes on board of directors

Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS

BioRestorative Ends Q3 In 'Strong' Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Eli Lilly

Interés en corto

Eli Lilly (NYSE:LLY) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL